Surgical and oncological score to estimate the survival benefit of resection and chemoradiotherapy in elderly (≥70 years) glioblastoma patients: A preliminary analysis.

Neurooncol Adv · 2022 · PMC8896333 · PMID 35261976

Europe PMC DOI

hedged sentences

0.0010

closest p · 0.0× alpha

0.0550

boldest claim

The sentences

markedly significantP < .001actually significant

Intraoperative use of 5ALA in patients undergoing surgical resection (ie excluding patients undergoing biopsy alone) was associated with a markedly significant mOS increase from 15.9 weeks (5ALA not used) to 45.4 weeks (5ALA used, Figure 2B ), P < .001.

also in 476 other papers

did not reach statistical significanceP = .055so close (0.05 < p ≤ 0.1)

A smaller benefit was also detected in MGMT-unmethylated patients, but it did not reach statistical significance (mOS 10.0 vs 7.9 months for patients with and without TMZ, respectively, P = .055).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.